Cholesterol Lowering in Intermediate-Risk Persons without Cardiovascular Disease — NEJM

Conclusions: Treatment with rosuvastatin at a dose of 10 mg per day resulted in a significantly lower risk of cardiovascular events than placebo in an intermediate-risk, ethnically diverse population without cardiovascular disease. (Funded by the Canadian Institutes of Health Research and AstraZeneca; HOPE-3 ClinicalTrials.gov number, NCT00468923.)

Source: Cholesterol Lowering in Intermediate-Risk Persons without Cardiovascular Disease — NEJM

Source: Blood-Pressure Lowering in Intermediate-Risk Persons without Cardiovascular Disease — NEJM

Source: Blood-Pressure and Cholesterol Lowering in Persons without Cardiovascular Disease — NEJM

Leave a comment